Translating groundbreaking science into tomorrow’s cures

Explore our science

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Explore our latest corporate presentation by clicking below to stay informed and gain valuable insights into our company’s vision, achievements, and roadmap.

View the corporate presentation

The Latest at Sangamo

News

Presentations

All Presentations

Publications

All Publications

Company pipeline and business development opportunities

Clinical Trials

CORE NEUROLOGY PIPELINE
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Anticipated Milestones*
Chronic Neuropathic Pain (Nav 1.7)	Data presented at ASGCT 2023				Q4 24: Nav 1.7 IND submission
Prion Disease	Data presented at Prion 2023				Q4 25: Prion CTA submission
Tauopathies					As early as Q4 25: Tau IND submission
ALS/FTD
Huntington's Disease

OTHER PROGRAMS
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Anticipated Milestones*
Hemophilia A (Giroctogene fitelparvovec)	Data presented at ASH 2023				Mid-2024: Phase 3 AFFINE trial pivotal readout Early 2025: BLA and MAA submissions
Fabry Disease (Isaralgagene civaparvovec)	Data presented at WORLDSymposium 2024				IH24: Phase 1/2 STAAR study dosing completion
Renal Transplant (TX200)	Six patients dosed in Phase 1/2				IH24: Phase 1/2 STEADFAST study dosing completion